Structure

InChI Key FBPFZTCFMRRESA-KVTDHHQDSA-N
Smile OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C6H14O6
Molecular Weight 182.17
AlogP -3.59
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 6.0
Number of Rotational Bond 5.0
Polar Surface Area 121.38
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 12.0

Pharmacology

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Brain Injuries 3 D001930 ClinicalTrials
Fetal Hypoxia 3 D005311 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials
Bronchiectasis 3 D001987 ClinicalTrials
Ciguatera Poisoning 3 D036841 ClinicalTrials
Brain Diseases 3 D001927 ClinicalTrials
Respiratory Sounds 3 D012135 ClinicalTrials
Malaria 3 D008288 ClinicalTrials
Hernias, Diaphragmatic, Congenital 3 D065630 ClinicalTrials
Shock, Septic 3 D012772 ClinicalTrials
Kidney Neoplasms 3 D007680 ClinicalTrials
Hearing Loss 2 D034381 ClinicalTrials
Osteoarthritis, Knee 2 D020370 ClinicalTrials
Pulpitis 2 D011671 ClinicalTrials
Stroke 2 D020521 ClinicalTrials
Sleep Apnea, Obstructive 2 D020181 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Hypotension 2 D007022 ClinicalTrials
Opioid-Related Disorders 2 D009293 ClinicalTrials
Glioma 1 D005910 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 1 D029424 ClinicalTrials
Pain 1 D010146 ClinicalTrials
Glioblastoma 1 D005909 ClinicalTrials
Diabetic Neuropathies 1 D003929 ClinicalTrials
Intracranial Hypertension 1 D019586 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 D015464 ClinicalTrials
Oligodendroglioma 1 D009837 ClinicalTrials
Central Nervous System Neoplasms 1 D016543 ClinicalTrials
Brain Neoplasms 1 D001932 ClinicalTrials
Neuralgia, Postherpetic 1 D051474 ClinicalTrials
Subarachnoid Hemorrhage 1 D013345 ClinicalTrials
Cognition 1 D003071 ClinicalTrials
Wounds and Injuries 1 D014947 ClinicalTrials

Related Entries

Mixture

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
15.34
Metabolism and nutrition disorders
13.86
Vascular disorders
11.68
Cardiac disorders
9.19
Nervous system disorders
8.8
Respiratory, thoracic and mediastinal disorders
6.67
Injury, poisoning and procedural complications
5.01
Immune system disorders
4.58
Renal and urinary disorders
3.83
Musculoskeletal and connective tissue disorders
3.66
Investigations
3.4
Ear and labyrinth disorders
3.05
Infections and infestations
2.44
Gastrointestinal disorders
2.18
Psychiatric disorders
2.18

Cross References

Resources Reference
CAS NUMBER 69-65-8
ChEBI 16899
ChEMBL CHEMBL689
DrugBank DB00742
DrugCentral 935
EPA CompTox DTXSID30858955
FDA SRS 3OWL53L36A
Human Metabolome Database HMDB00765
KEGG C00392
PDB MTL
PubChem 6251
SureChEMBL SCHEMBL919
ZINC ZINC000002041302